These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31504342)

  • 1. Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency.
    Mngqibisa R; Kendall MA; Dooley K; Wu XS; Firnhaber C; Mcilleron H; Robinson J; Cramer Y; Rosenkranz SL; Roa J; Coughlin K; Mawlana S; Badal-Faesen S; Schnabel D; Omoz-Oarhe A; Samaneka W; Godfrey C; Cohn SE;
    Clin Infect Dis; 2020 Jul; 71(3):517-524. PubMed ID: 31504342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.
    Haas DW; Mngqibisa R; Francis J; McIlleron H; Robinson JA; Kendall MA; Baker P; Mawlana S; Badal-Faesen S; Angira F; Omoz-Oarhe A; Samaneka WP; Denti P; Cohn SE;
    Pharmacogenet Genomics; 2022 Jan; 32(1):24-30. PubMed ID: 34369424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.
    Luque AE; Cohn SE; Park JG; Cramer Y; Weinberg A; Livingston E; Klingman KL; Aweeka F; Watts DH
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2094-101. PubMed ID: 25624326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
    Nanda K; Callahan R; Taylor D; Wang M; Agot K; Jenkins D; Van Damme L; Dorflinger L;
    Contraception; 2016 Jul; 94(1):40-7. PubMed ID: 26972780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women.
    Weinberg A; Park JG; Bosch R; Cho A; Livingston E; Aweeka F; Cramer Y; Watts DH; Luque AE; Cohn SE
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):137-45. PubMed ID: 26413850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi.
    Zia Y; Tang JH; Chinula L; Tegha G; Stanczyk FZ; Kourtis AP
    Contraception; 2019 Nov; 100(5):402-405. PubMed ID: 31374188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
    Francis J; Mngqibisa R; McIlleron H; Kendall MA; Wu X; Dooley KE; Firnhaber C; Godfrey C; Cohn SE; Denti P;
    Clin Pharmacol Ther; 2021 Oct; 110(4):1057-1065. PubMed ID: 34151439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of depot medroxyprogesterone acetate contraception.
    Mishell DR
    J Reprod Med; 1996 May; 41(5 Suppl):381-90. PubMed ID: 8725700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women.
    Rahimy MH; Ryan KK
    Contraception; 1999 Oct; 60(4):189-200. PubMed ID: 10640165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.
    Watts DH; Park JG; Cohn SE; Yu S; Hitti J; Stek A; Clax PA; Muderspach L; Lertora JJ
    Contraception; 2008 Feb; 77(2):84-90. PubMed ID: 18226670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women.
    Toh YC; Jain J; Rahnny MH; Bode FR; Ross D
    Clin Ther; 2004 Nov; 26(11):1845-54. PubMed ID: 15639696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone density in long term users of depot medroxyprogesterone acetate.
    Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
    Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.
    Ortiz A; Hirol M; Stanczyk FZ; Goebelsmann U; Mishell DR
    J Clin Endocrinol Metab; 1977 Jan; 44(1):32-8. PubMed ID: 833262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of endogenous progesterone levels in young women using hormonal contraception with recent HIV-1 infection.
    Boodhram R; Moodley D; Abbai N; Ramjee G
    BMC Womens Health; 2019 May; 19(1):63. PubMed ID: 31068152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa.
    Smith JA; Beacroft L; Abdullah F; Buthelezi B; Makua M; Morroni C; Ramjee G; Velasquez C; Hallett TB
    J Int AIDS Soc; 2020 Oct; 23(10):e25620. PubMed ID: 33030312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
    Dragoman MV; Gaffield ME
    Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques.
    Radzio J; Hanley K; Mitchell J; Ellis S; Deyounks F; Jenkins LT; Hanson D; Heneine W; García-Lerma JG
    AIDS; 2014 Jun; 28(10):1431-9. PubMed ID: 24759208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
    Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
    Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
    Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
    BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.